The EPS miss and continued cash burn without near-term revenue catalysts suggest downside risk. Monitor for KOMODO-1 proof-of-concept data readout, which is the primary value driver. The $92.8M cash runway into H2 2028 provides some buffer but does not offset the lack of fundamental progress.
Price Chart
Executive Summary
Boundless Bio reported Q1 2026 net loss of $13.6M ($0.60/share), wider than the consensus estimate of $0.56 loss per share. The company highlighted ongoing enrollment in its KOMODO-1 trial for BBI-940 and a cash runway of $92.8M into H2 2028, but the EPS miss and lack of revenue (pre-revenue biotech) reinforce the bearish sentiment given the stock's small market cap and high cash burn rate.
Key Financial Metrics
Key Facts
- Net loss of $13.6M for Q1 2026, compared to $15.8M in Q1 2025
- EPS of -$0.60 vs consensus -$0.56 (miss of 7.1%)
- Cash, cash equivalents, and short-term investments totaled $92.8M as of March 31, 2026
- R&D expenses decreased to $9.7M from $12.1M year-over-year
- G&A expenses decreased to $4.7M from $5.2M year-over-year
- Enrollment ongoing in KOMODO-1 first-in-human trial of BBI-940 for ER+/HER2- breast cancer and TNBC-LAR
- Company expects cash to fund operations into second half of 2028
Financial Impact
EPS miss of $0.04 per share (7.1% below consensus) on a net loss of $13.6M; cash burn of ~$14.7M in Q1 2026
Risk Factors
- Clinical trial delays or negative data from KOMODO-1 could significantly impair stock value
- Cash burn rate of ~$14.7M per quarter implies ~6.3 quarters of runway, potentially requiring dilutive financing before proof-of-concept readout
- No approved products or revenue, making the stock highly speculative and binary on trial outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290993 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 425 | — | awaiting T+20 | — | — |
Oct 8, 2026 17d ago | S-4 | $2.53 | awaiting T+20 | — | $2.40 (+5.14%) |
Aug 28, 2026 8w ago | 425 / 8-K | $2.81 $2.56 | ▼ −8.90% | ▼ −8.53% | $2.40 (−14.59%) |
Jul 8, 2026 15w ago | Insider Cluster | $2.51 $2.84 | ▲ +13.15% | ▲ +10.91% | $2.40 (−4.38%) |
Jul 6, 2026 15w ago | Insider Cluster | $2.50 $2.71 | ▲ +8.20% | ▲ +5.04% | $2.40 (−4.00%) |
Jun 29, 2026 16w ago | 3 | $2.50 $2.48 | ▼ −0.80% | ▲ +0.23% | $2.40 (−4.00%) |
May 8, 2026 24w ago | 8-K | $1.44 $1.42 | ▼ −1.39% | ▼ −1.41% | $2.40 (+66.67%) |
May 8, 2026 24w ago | Press Release | $1.44 $1.42 | ▲ +1.39% | ▲ +1.41% | $2.40 (−66.67%) |
Apr 17, 2026 27w ago | Press Release | $1.60 $1.42 | ▼ −11.25% | ▼ −15.45% | $2.40 (+50.00%) |
Apr 13, 2026 27w ago | 8-K | $1.56 $1.55 | ▲ +0.64% | ▲ +6.94% | $2.40 (−53.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers